The Journal of Nutrition Health and Aging

, Volume 12, Issue 7, pp 470–478 | Cite as

Target population for clinical trials on sarcopenia

Article

Abstract

The term “sarcopenia” describes the progressive decline of muscle mass, strength and function occurring with aging. It is not considered a disease, but the direct consequence of the aging process on the skeletal muscle. Multiple demographic (e.g. gender, race), biological (e.g. inflammatory status) and clinical (e.g. diabetes, metabolic syndrome, congestive heart failure, medications) factors are able to influence (positively or negatively) the skeletal muscle quality and quantity. The extreme paucity of clinical trials on sarcopenia in literature is mainly due to difficulties in designing studies able to isolate the aging process from its multiple and interconnected consequences. In the present review, we present the major factors to consider as potential sources of biased results when evaluating potential candidates for clinical trials on sarcopenia. The development of clinical trials exploring the nature of the sarcopenia process is urgent, but several controversial issues on this hallmark of aging still need clarification.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997; 127:E790-E800.Google Scholar
  2. 2.
    Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147(8):755–763.PubMedGoogle Scholar
  3. 3.
    Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001; 137:231–243.PubMedGoogle Scholar
  4. 4.
    Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3):M146-M156.PubMedGoogle Scholar
  5. 5.
    Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C et al. Frailty syndrome and skeletal muscle - Results from the InCHIANTI study. Am J Clin Nutr 2006; 83(5):1142–1148.PubMedGoogle Scholar
  6. 6.
    Kenny WL, Buskirk ER. Functional consequences of sacropenia: effects on thermoregulation. J Gerontol 1995; 50A:101–106.Google Scholar
  7. 7.
    Poehlman E. Regulation of energy expenditure in aging humans. J Am Geriatr Soc 1993; 13:469–488.Google Scholar
  8. 8.
    Raphael D, Cava M, Brown I, Renwick R, Heartcote K, Weir N et al. Frailty: a public health perspective. Can J Public Health 1995; 86:224–227.PubMedGoogle Scholar
  9. 9.
    Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6(2):123–130.PubMedGoogle Scholar
  10. 10.
    Rantanen T, Guralnik JM, Foley D, Masaki K, Leveille SG, Curb JD et al. Midlife hand grip strength as a predictor of old age disability. JAMA 1999; 281:558–560.PubMedGoogle Scholar
  11. 11.
    Metter EJ, Talbot LA, Schrager M, Conwit R. Skeletal muscle strength as a predictor of all-cause mortality in healthy men. J Gerontol A Biol Sci Med Sci 2002; 57:B359-B365.PubMedGoogle Scholar
  12. 12.
    Janssen I, Shepard D, Katzmarzyk P, Roubenoff R. The health care costs of sarcopenia in the United States. J Am Geriatr Soc 2004; 52:80–85.PubMedGoogle Scholar
  13. 13.
    Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Fiatarone Singh MA. Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. Am J Clin Nutr 2002; 76:473–481.PubMedGoogle Scholar
  14. 14.
    Herndon LA, Schmeissner PJ, Dudaronek JM, Brown PA, Listner KM, Sakano Y et al. Stochastic and genetic factors influence tissue-specific decline in ageing C. elegans. Nature 2002; 419(6909):808–814.PubMedGoogle Scholar
  15. 15.
    Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M Rubin SM et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005; 60A(3):324–333.Google Scholar
  16. 16.
    Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB et al. Strength, but not muscle mass, is associated with mortality in the Health, Aging and Body Composition Study cohort. J Gerontol A Biol Sci Med Sci 2006; 61 A(1):72–77.PubMedGoogle Scholar
  17. 17.
    Bortz WM II. A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med Sci 2002; 57A:M283-M288.Google Scholar
  18. 18.
    Melton LJ, III, Khosla S, Riggs BL. Epidemiology of sarcopenia. Mayo Clin Proc 2000;75(Suppl):S10-S13.PubMedGoogle Scholar
  19. 19.
    Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50:889–896.PubMedGoogle Scholar
  20. 20.
    Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C., Di Iorio A et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 2003; 95:1851–1860.PubMedGoogle Scholar
  21. 21.
    Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. J Appl Physiol 2000; 89:81–88.PubMedGoogle Scholar
  22. 22.
    Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M Stamm E et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the Health, Aging, and Body Composition study. J Am Geriatr Soc 2002; 50(5):897–904.PubMedGoogle Scholar
  23. 23.
    Hughes VA, Frontera WR, Wood M, Evans WJ, Dallai GE, Roubenoff R et al. Longitudinal muscle changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci 2001; 56(5):B209-B217.PubMedGoogle Scholar
  24. 24.
    Aloia JF, Vaswani A, Russo L, Sheehan M, Flaster E. The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass. Am J Obster Gynecol 1995; 172(3):896–900.Google Scholar
  25. 25.
    Phillips SK, Rook KM, Siddle NC., Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993; 84(1):95–98.Google Scholar
  26. 26.
    Wang Z, Heo M, Lee RC, Kotler DP, Withers RT, Heymsfield SB. Muscularity in adult humans: proportion of adipose tissue-free body mass as skeletal muscle. Am J Hum Biol 2001; 13(5):612–619.PubMedGoogle Scholar
  27. 27.
    Castaneda C, Janssen I. Ethnic comparisons of sarcopenia and obesity in diabetes. Ethn Dis 2005; 15(4):664–670.PubMedGoogle Scholar
  28. 28.
    Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000; 72:694–701.PubMedGoogle Scholar
  29. 29.
    Rush EC, Goedecke JH, Jennings C, Micklesfield L, Dugas L, Lambert EV et al. BMI, fat and muscle differences in urban women of five ethnicities from two countries. Int J Obes (Lond) 2007; 31(8):1232–1239.Google Scholar
  30. 30.
    Duncan BB, Chambless LE, Schmidt MI, Szklo M, Folsom AR, Carpenter MA et al. Correlates of body fat distribution. Variation across categories of race, sex, and body mass in the atherosclerosis risk in communities study. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol 1995; 5(3):192–200.PubMedGoogle Scholar
  31. 31.
    Roubenoff R. Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Ann N Y Acad Sci 2000; 904:553–557.PubMedGoogle Scholar
  32. 32.
    Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res 2004; 12(6):887–888.PubMedGoogle Scholar
  33. 33.
    Castaneda C, Charnley JM, Evans WJ, Crim MC. Elderly women accomodate to a low-protein diet with losses of body cell mass, muscle function, and immune response. Am J Clin Nutr 1995; 62:30–39.PubMedGoogle Scholar
  34. 34.
    Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr 2004; 80(2):496–503.PubMedGoogle Scholar
  35. 35.
    Castillo EM, Goodman-Gruen D, Kritz-Silverstein D, Morton DJ, Wingard DL, Barrett-Connor E. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am J Prev Med 2003; 25(3):226–231.PubMedGoogle Scholar
  36. 36.
    Yanbaeva DG, Dentener MA, Creutzberg EG, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007; 131(5):1557–1566.PubMedGoogle Scholar
  37. 37.
    Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM Shyr Y et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198–1203.PubMedGoogle Scholar
  38. 38.
    Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G et al. Effects of vitamin E supplementation on F2-Isoprostane and Thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000; 102:539–545.PubMedGoogle Scholar
  39. 39.
    Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci 1989; 86:6377–6381.PubMedGoogle Scholar
  40. 40.
    Levitzky YS, Guo CY, Rong J, Larson MG, Walter RE, Keaney JF, Jr. et al. Relation of smoking to a panel of inflammatory markers: The Framingham offspring. Atherosclerosis 2008; in press.Google Scholar
  41. 41.
    Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des 2007; 13(16):1661–1667.PubMedGoogle Scholar
  42. 42.
    Cacciola RR, Guarino F, Polosa R. Relevance of endothelial-haemostatic dysfunction in cigarette smoking. Curr Med Chem 2007; 14(17):1887–1892.PubMedGoogle Scholar
  43. 43.
    Petersen AM, Magkos F, Atherton P, Selby A, Smith K, Rennie MJ et al. Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. Am J Physiol Endocrinol Metab 2007; 293(3):E843-E848.PubMedGoogle Scholar
  44. 44.
    Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330(25):1769–1775.PubMedGoogle Scholar
  45. 45.
    Larsson L. Physical training effects on muscle morphology in sedentary males at different ages. Med Sci Sports Exerc 1982; 14:203–206.PubMedGoogle Scholar
  46. 46.
    Hagerman FC, Walsh SJ, Staron RS, Hikida RS, Gilders RM, Murray TF et al. Effects of high-intensity resistance training on untrained older men. I — Strength, cardiovascular, and metabolic responses. J Gerontol A Biol Sci Med Sci 2000; 55(7):B336-B346.PubMedGoogle Scholar
  47. 47.
    Hikida RS, Staron RS, Hagerman FC, Walsh SJ, Kaiser E, Shell S et al. Effects of high-intensity resistance training on untrained older men. II — Muscle fiber characteristics and nucleo-cytoplasmatic relationships. J Gerontol A Biol Sci Med Sci 2000; 55(7):B347-B354.PubMedGoogle Scholar
  48. 48.
    Yarasheski KE, Pak-Loduca J, Hasten DL, Obert KA, Brown MB, Sinacore DR. Resistance exercise training increases mixed muscle protein synthesis rate in frail womena and men >/= 76 yr old. Am J Physiol 1999; 277(1 Pt 1):E118-E125.PubMedGoogle Scholar
  49. 49.
    Balagopal P, Schimke JC, Ades P, Nair KS. Age effect on transcript levels and synthesis rate of muscle MHC and response to resistance exercise. Am J Physiol Endocrinol Metab 2001; 280:E203-E208.PubMedGoogle Scholar
  50. 50.
    Hasten DL, Pak-Loduca J, Obert KA, Yarasheski KE. Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78–84 and 23–32 yr olds. Am J Physiol Endocrinol Metab 2000; 278(4):E620-E626.PubMedGoogle Scholar
  51. 51.
    Welle S, Thornton C, Statt M. Myofibrillar protein synthesis in young and old human subjects after three months of resistance training. Am J Physiol 1995; 268:E422-E427.PubMedGoogle Scholar
  52. 52.
    Balagopal P, Rooyackers OE, Adey DB, Ades PA, Nair KS. Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol Endocrinol Metab 1997; 273:E790-E800.Google Scholar
  53. 53.
    Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S et al. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol 2004; 39:17–24.PubMedGoogle Scholar
  54. 54.
    Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol 2005; 78(4): 819–835.PubMedGoogle Scholar
  55. 55.
    Rooks DS, Kiel DP, Parsons C, Hayes WC. Self-paced resistance training and walking exercise in community-dwelling older adults: effects on neuromotor performance. J Gerontol A Biol Sci Med Sci 1997; 52(3):M161-M168.PubMedGoogle Scholar
  56. 56.
    Evans WJ. Protein, nutrition and aging. J Am Coll Nutr 2004; 23(Suppl 6):601S-609S.PubMedGoogle Scholar
  57. 57.
    Bermon S, Hebuterne X, Peroux JL, Marconnet P, Rampai P. Correction of proteienergy malnutrition in older adults: effects of a short-term aerobic training program. Clin Nutr 1997; 16(6):291–298.PubMedGoogle Scholar
  58. 58.
    Beere PA, Russell SD, Morey MC, Kitzman DW, Higginbotham MB. Aerobic exercise training can reserve age-related peripheral circulatory changes in healthy older men. Circulation 1999; 100:1085–1094.PubMedGoogle Scholar
  59. 59.
    Ogawa T, Spina RJ, Martin WH, III, Kohrt WM, Schechtman KB, Holloszy JO et al. Effects of aging, sex, and physical training on cardiovascular responses to exercise. Circulation 1992; 86:494–503.PubMedGoogle Scholar
  60. 60.
    Hagberg JM, Graves JE, Limacher M, Woods DR, Leggett SH, Cononie C et al. Cardiovascular responses of 70- to 79-yr-old men and women to exercise training. J Appl Physiol 1989; 66:2589–2594.PubMedGoogle Scholar
  61. 61.
    Messier SP, Loeser RF, Miller GD, Morgan TM, Rejeski WJ, Sevick MA et al. Exercise and diet weight loss in overweigh and obese older adults with knee osteoarthritis — The Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004; 50(5):1501–1510.PubMedGoogle Scholar
  62. 62.
    Miller GD, Nicklas BJ, Loeser RF. Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 2008; 56(4): 644–651.PubMedGoogle Scholar
  63. 63.
    Morley JE. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des 2007; 13(35):3637–3647.PubMedGoogle Scholar
  64. 64.
    Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51:245–270.PubMedGoogle Scholar
  65. 65.
    Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20:683–693.PubMedGoogle Scholar
  66. 66.
    Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumor necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem 1993; 125:11–18.PubMedGoogle Scholar
  67. 67.
    Hoshino E, Pichard C, Greenwood CE, Huo GC, Cameron RG, Kurian R et al. Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol 1991; 260:E27-E36.PubMedGoogle Scholar
  68. 68.
    Charters Y, Grimble RF. Effects of recombinant human tumor necrosis factor alpha on protein synthesis in liver, skeletal muscle and skin of rats. Biochem J 1989; 258:493–497.PubMedGoogle Scholar
  69. 69.
    Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003; 6(3):295–299.PubMedGoogle Scholar
  70. 70.
    Visser M Pahor M Taaffe DR, Goodpaster BH, Simonsick EM Newman AB et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC study. J Gerontol A Biol Sci Med Sci 2002; 57A(5):M326-M332.Google Scholar
  71. 71.
    Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Williams GR et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59A(3):M242-M248.Google Scholar
  72. 72.
    Phillips T, Leeuwenburgh C. Muscle fiber-specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J 2005; 19:668–670.PubMedGoogle Scholar
  73. 73.
    Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. FASEB J 2001; 15:984–995.Google Scholar
  74. 74.
    Roubenoff R, Parise H, Payette HA, Abad LW, D’Agostino RB, Jacques PF et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 2003; 115:429–435.PubMedGoogle Scholar
  75. 75.
    Chandalia M, Abate N. Metabolic complications of obesity: inflated or inflamed? J Diabetes Complications 2007; 21(2):128–136.PubMedGoogle Scholar
  76. 76.
    Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Muscle wasting in cancer and ageing: cachexia versus sarcopenia. Adv Gerontol 2006; 18:39–54.PubMedGoogle Scholar
  77. 77.
    Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7:271–277.PubMedGoogle Scholar
  78. 78.
    Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab 2003; 88(1):358–362.PubMedGoogle Scholar
  79. 79.
    Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998; 275(5 Pt 1):E864-E871.PubMedGoogle Scholar
  80. 80.
    Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144(11):5081–5088.PubMedGoogle Scholar
  81. 81.
    Lissett CA, Shalet SM. Effects of growth hormone on bone and muscle. Growth Horm IGF Res 2000; 10(Suppl B):S95-S101.PubMedGoogle Scholar
  82. 82.
    Jorgensen JO, Vahl N, Hansen TB, Skjaerbaek C, Fisker S, Orskov H et al. Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects. Clin Endocrinol (Oxf) 1998; 48(4):479–486.Google Scholar
  83. 83.
    Karakelides H, Nair KS. Sarcopenia of aging and its metabolic impact. Curr Top Dev Biol 2005; 68:123–148.PubMedGoogle Scholar
  84. 84.
    de Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI et al. Diabetes, hyperglycemia, and inflammation in older individuals: the Health, Aging and Body Composition study. Diabetes Care 2006; 29(8):1902–1908.PubMedGoogle Scholar
  85. 85.
    Figaro MK, Kritchevsky SB, Resnick HE, Shorr RI, Butler J, Shintani A et al. Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care 2006; 29(9):2039–2045.PubMedGoogle Scholar
  86. 86.
    Azuma K, Heilbronn LK, Albu JB, Smith SR, Ravussin E, Kelley DE et al. Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2007; 293(1):E435-E442.PubMedGoogle Scholar
  87. 87.
    Cesari M Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003; 92(5):522–528.PubMedGoogle Scholar
  88. 88.
    Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007; 93(8):903–907.PubMedGoogle Scholar
  89. 89.
    Hanly PJ, Millar TW, Steljes DG, Baert R, Frais MA, Kryger MH. Respiration and abnormal sleep in patients with congestive heart failure. Chest 1989; 96(3):480–488.PubMedGoogle Scholar
  90. 90.
    Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83(4):735–743.PubMedGoogle Scholar
  91. 91.
    Poehlman E, Toth M, Fishman P, Vaitkevicius P, Gottlieb S, Fisher M et al. Sarcopenia in aging humans: the impact of menopause and disease. J Gerontol A Biol Sci Med Sci 1995;50(Spec No):73–77.PubMedGoogle Scholar
  92. 92.
    Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarlhritic subchondral bone. Cytokine 2007; 38(3):151–156.PubMedGoogle Scholar
  93. 93.
    Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM et al. Anemia and hemoglobin levels in older persons: relationship with age, gender and health status. J Am Geriatr Soc 1992; 40:489–496.PubMedGoogle Scholar
  94. 94.
    Cesari M, Penninx BWJH, Lauretani F, Russo CR, Carter C, Bandinelli S et al. Hemoglobin levels and skeletal muscle: results from the InCHJANTI study. J Gerontol A Biol Sci Med Sci 2004; 59A(3):249–254.Google Scholar
  95. 95.
    Boogaerts M, Coiffier B, Kainz C. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Canc 2003; 88:988–995.Google Scholar
  96. 96.
    Lipschitz D. Medical and functional consequences of anemia in the elderly. J Am Geriatr Soc 2003;51:S10-S13.PubMedGoogle Scholar
  97. 97.
    Williams C. Hemoglobin — is more better? Nephrol Dial Transplant 1995; 10(Suppl 2):48–55.PubMedGoogle Scholar
  98. 98.
    Penninx BWJH, Guralnik JM, Onder G, Ferrucci L, Wallace RB, Pahor M. Anemia and decline in physical performance among older persons. Am J Med 2003; 115(2):104–110.PubMedGoogle Scholar
  99. 99.
    Tinetti ME, Williams CS, Gill TM. Health, functional, and psychological outcomes among older persons with chronic dizziness. J Am Geriatr Soc 2000; 48(4):417–421.PubMedGoogle Scholar
  100. 100.
    Dodd SL, Powers SK, Brooks E, Crawford MP. Effects of reduced O2 delivery with anemia, hypoxia, or ischemia on peak VO2 and force in skeletal muscle. J Appl Physiol 1993;74(1):186–191.PubMedGoogle Scholar
  101. 101.
    Cerretelli P. Muscle energetics and ultrastructure in chronic hypoxia. Respiration 1992; 59(Suppl 2):24–29.PubMedGoogle Scholar
  102. 102.
    Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114:112–119.PubMedGoogle Scholar
  103. 103.
    Silverberg DS, Iaina A, Wexler D, Blum M. The pathological consequences of anaemia. Clin Lab Haem 2001; 23:1–6.Google Scholar
  104. 104.
    Mak RH, Rotwein P. Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation. Kidney Int 2006; 70:410–412.PubMedGoogle Scholar
  105. 105.
    Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr 1996; 64(4):552–558.PubMedGoogle Scholar
  106. 106.
    Tchernof A, Labrie F. Dehydroepiandrosterone, obesity, and cardiovascular disese risk: a review of human studies. Eur J Endocrinol 2004; 151(1):1–14.PubMedGoogle Scholar
  107. 107.
    Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49(4):421–432.Google Scholar
  108. 108.
    Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66:57–61.PubMedCrossRefGoogle Scholar
  109. 109.
    Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoidtreated men. Arch Intern Med 1996; 156(11):1173–1177.PubMedGoogle Scholar
  110. 110.
    Sih R, Morley JE, Kaiser FE, Perry HM3, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 826(1661):1667.Google Scholar
  111. 111.
    Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75(4):1092–1098.PubMedGoogle Scholar
  112. 112.
    Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269:E820-E826.PubMedGoogle Scholar
  113. 113.
    Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle protein synthesis in hypogonadal men — A clinical research center study. J Clin Endocrinol Metab 1996; 81:3469–3475.PubMedGoogle Scholar
  114. 114.
    Gregory CM, Vandenborne K, Huang HF, Ottenweller JE, Dudley GA. Effects of testosterone replacement therapy on skeletal muscle after spinal cord injury. Spinal Cord 2003;41(1):23–28.PubMedGoogle Scholar
  115. 115.
    Hadi Mansouri S, Siegford JM, Ulibarri C. Early postnatal response of the spinal nucleus of the bulbocavernosus in the adult male gerbils. Brain Res Dev Brain Res 2003; 142:129–139.PubMedGoogle Scholar
  116. 116.
    Greenlund LJS, Nair KS. Sarcopenia — Consequences, mechanisms, and potential therapies. Mech Age Dev 2003; 124:287–299.Google Scholar
  117. 117.
    Welle S, Thornton C, Statt M McHenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81:3239–3243.PubMedGoogle Scholar
  118. 118.
    Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1–6.PubMedGoogle Scholar
  119. 119.
    Butterfield GE, Thompson J, Rennie MJ, Marcus R, Hintz RL, Hoffman AR. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol 1997; 272:E94-E99.PubMedGoogle Scholar
  120. 102.
    Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177:1675–1680.PubMedGoogle Scholar
  121. 121.
    Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54:540–545.PubMedGoogle Scholar
  122. 122.
    Khan ZH, Simpson EJ, Cole AT, Holt M, MacDonald I, Pye D et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003; 17(5):677–682.PubMedGoogle Scholar
  123. 123.
    Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 1994; 84(8):2472–2479.PubMedGoogle Scholar
  124. 124.
    Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci 2000; 904:437–448.PubMedCrossRefGoogle Scholar
  125. 125.
    Launer LJ, Harris T, Rumpel C, Madans J. Body mass index, weight change and risk of mobility disability in middle-aged and older women. The epidemiologic follow-up of NHANES I. JAMA 1994; 271(14):1093–1098.PubMedGoogle Scholar
  126. 126.
    Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47:639–646.PubMedGoogle Scholar
  127. 127.
    Yudkin JS, Kumari M Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148:209–214.PubMedGoogle Scholar
  128. 128.
    Nicklas BJ, Penninx BWJH, Cesari M, Kritchevsky SB, Newman AB, Kanaya AM et al. Relationship of visceral adipose tissue to incident myocardial infarction in older men and women: the Health, Aging and Body Composition study. Am J Epidemiol 2004; 160(8):741–749.PubMedGoogle Scholar
  129. 129.
    Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Nevitt MC et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003; 51(11):1602–1609.PubMedGoogle Scholar
  130. 130.
    Cesari M Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BWJH, Lenchik L et al. Sarcopenia, obesity and inflammation — Results from the TRAIN study. Am J Clin Nutr 2005; 82:428–434.PubMedGoogle Scholar
  131. 131.
    Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37:614–636.PubMedGoogle Scholar
  132. 132.
    Hayflick L. “Anti-Aging” is an oxymoron. J Gerontol A Biol Sci Med Sci 2004; 59A(6):573–578.Google Scholar
  133. 133.
    Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 1990; 263(22):3029–3034.PubMedGoogle Scholar

Copyright information

© Springer-Verlag France and Serdi Éditions 2008

Authors and Affiliations

  1. 1.Department of Aging and Geriatric ResearchUniversity of Florida - Institute on AgingGainesville

Personalised recommendations